Hepatoid Adenocarcinoma of the Lung

Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. HAL morphologically and pathologically exhibits hepatocellular carcinoma (HCC)-like characteristics, while its clinical features resemble pulmonary adenocarcinoma. High...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meihui Li, Ying Fan, Hongyang Lu
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ac39c152975744ad89e8d3f07442d820
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac39c152975744ad89e8d3f07442d820
record_format	dspace
spelling	oai:doaj.org-article:ac39c152975744ad89e8d3f07442d8202021-12-02T01:04:31ZHepatoid Adenocarcinoma of the Lung1533-033810.1177/15330338211057983https://doaj.org/article/ac39c152975744ad89e8d3f07442d8202021-11-01T00:00:00Zhttps://doi.org/10.1177/15330338211057983https://doaj.org/toc/1533-0338Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. HAL morphologically and pathologically exhibits hepatocellular carcinoma (HCC)-like characteristics, while its clinical features resemble pulmonary adenocarcinoma. High concentration of alpha-fetoprotein (AFP) is often detected in the serum of HAL patients with no hepatic occupying lesion. Patients with AFP-negative HAL survive a few months longer than those with positive AFP test. HAL is a rare type of carcinoma, so there is a lack of systematic and extensive statistical research. The treatment strategy for HAL is similar to common lung adenocarcinoma. Complete surgical resection and adjuvant chemotherapy are the current major treatments for HAL patients. There are also a few of case reports suggesting that HAL patients may benefit from immunotherapy and targeted therapy. This review focuses on the clinical and pathological features, immunohistochemical staining characteristics, treatment and prognosis of HAL.Meihui LiYing FanHongyang LuSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Meihui Li Ying Fan Hongyang Lu Hepatoid Adenocarcinoma of the Lung
description	Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. HAL morphologically and pathologically exhibits hepatocellular carcinoma (HCC)-like characteristics, while its clinical features resemble pulmonary adenocarcinoma. High concentration of alpha-fetoprotein (AFP) is often detected in the serum of HAL patients with no hepatic occupying lesion. Patients with AFP-negative HAL survive a few months longer than those with positive AFP test. HAL is a rare type of carcinoma, so there is a lack of systematic and extensive statistical research. The treatment strategy for HAL is similar to common lung adenocarcinoma. Complete surgical resection and adjuvant chemotherapy are the current major treatments for HAL patients. There are also a few of case reports suggesting that HAL patients may benefit from immunotherapy and targeted therapy. This review focuses on the clinical and pathological features, immunohistochemical staining characteristics, treatment and prognosis of HAL.
format	article
author	Meihui Li Ying Fan Hongyang Lu
author_facet	Meihui Li Ying Fan Hongyang Lu
author_sort	Meihui Li
title	Hepatoid Adenocarcinoma of the Lung
title_short	Hepatoid Adenocarcinoma of the Lung
title_full	Hepatoid Adenocarcinoma of the Lung
title_fullStr	Hepatoid Adenocarcinoma of the Lung
title_full_unstemmed	Hepatoid Adenocarcinoma of the Lung
title_sort	hepatoid adenocarcinoma of the lung
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/ac39c152975744ad89e8d3f07442d820
work_keys_str_mv	AT meihuili hepatoidadenocarcinomaofthelung AT yingfan hepatoidadenocarcinomaofthelung AT hongyanglu hepatoidadenocarcinomaofthelung
_version_	1718403338121248768

Hepatoid Adenocarcinoma of the Lung

Ejemplares similares